Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model

Li, Xingxing; Wu, Shuo; Du, Yu; Yang, Lu; Li, Yuhuan; Hong, Bin

doi:10.1016/j.ijantimicag.2020.106000

Cited by 21 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 28–31 Interestingly, one common feature for all of those conditions is a poor representation of A. muciniphila . 5 , 32 , 33 In the same line, A. muciniphila has been suggested to exert neuroprotective effects 2 , 5 and it is worth underlining that 2-methylbutyrylglycine is a metabolite described as a neurotoxin and that A. muciniphila treated subjects had lower levels of this metabolite. 34 Effects of living A. muciniphila were also characterized by an elevation of circulating levels of gluconate and 3-hydroxyhexanoylcarnitine.…”

Section: Discussionmentioning

confidence: 93%

Serum metabolite profiling yields insights into health promoting effect of A. muciniphila in human volunteers with a metabolic syndrome

et al. 2021

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

Serum metabolite profiling yields insights into health promoting effect of A. muciniphila in human volunteers with a metabolic syndrome

et al. 2021

View full text Add to dashboard Cite

“…Li et al [22] established a recombinant adeno-associated virus serotype 8 (rAAV8)-mediated continuous HBV infection mouse model. Results showed that entecavir could significantly reduce HBV DNA in the serum and liver.…”

Section: Discussionmentioning

confidence: 99%

Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study

Wang

et al. 2020

Infect Dis Ther

View full text Add to dashboard Cite

Introduction This study aimed to analyze the diversity of intestinal flora in patients with chronic hepatitis B (CHB) and investigate the effect of entecavir on the intestinal flora in these patients. Methods Thirty patients with CHB and 30 healthy controls were recruited from the Department of Infectious Diseases and Department of Gastroenterology of Shanghai Tongji Hospital between January 2017 and December 2018. Stool samples were collected for the detection of intestinal flora by high-throughput sequencing. Patients with CHB received antivirus therapy with entecavir for 8 weeks. The biochemical and virological responses were assessed and the intestinal flora were compared. Results After entecavir treatment, the blood levels of alanine aminotransferase (ALT), interleukin-6 (IL-6), IL-8, tumor necrosis factor (TNF), and hepatitis B virus (HBV) DNA reduced significantly in patients with CHB and the species abundance of intestinal flora increased markedly. In patients with CHB, the unique genera included Butyrivibrio , Phaseolus acutifolius , and Prevotellaceae NK3B31 group before treatment and Howardella , Candidatus Stoquefichus , Citrobacter , Dysgonomonas , Faecalicoccus , Methanobrevibacter , Mitsuokella , Mobilitalea , Succinivibrio , Gluconobacter , and Plesiomonas after treatment. The abundance of the following genera increased significantly after entecavir treatment in patients with CHB: Clostridium sensu stricto 1, Erysipelotrichaceae UCG-007, and Intestinibacter . The abundance of Streptococcus , Atopobium , and Murdochiella reduced markedly after entecavir treatment in patients with CHB. Conclusion After 8-week entecavir treatment, the blood biochemical, immunological, and virological responses improved significantly, the species abundance of intestinal flora increased markedly, and there were unique genera in patients with CHB before and after treatment. Electronic supplementary material The online version of this article (10.1007/s40121-020-00355-w) contains supplementary material, which is available to authorized users.

show abstract

“…Metabolic‐associated fatty liver disease patients likewise show increased intestinal permeability and impaired bile acid homeostasis, 42 with increasing evidence suggesting that gut dysbiosis may be accelerating progression from simple steatosis to steatohepatitis 40 . Growing evidence suggest that gut dysbiosis and CHB infection may interact similar to other liver diseases, and this review aims to recapitulate the current data pertaining to CHB infection 44 …”

Section: The Role Of Gut‐liver Axis In Liver Diseasementioning

confidence: 99%

The role of gut microbiota in hepatitis B disease progression and treatment

Chen

Huang

Pan

2021

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Current therapeutic interventions can only suppress hepatitis B virus (HBV) replication or reduce complications without a cure. Therefore, further development of new treatment methods is critical for the global eradication of HBV. Accumulating evidence suggests that the liver and gut share an interconnected relationship referred to as the 'Gut-Liver Axis', where exchanges happen bi-directionally. The gut itself is the host to a unique microbiota profile which has metabolic, immunological, neurological and nutritional functions. Gut microbiota is not only constantly intersecting with the liver but also associated with hepatic injury when dysbiosis occurs. In recent years, there has been increased interest in gut microbiota and its implications on liver disease treatment. Progress has been made in understanding the complex relationship between chronic hepatitis B (CHB) and gut microbiota. New investigative techniques such as colony-free sequencing enabled new perspectives into this field.Mouse models and human studies revealed that HBV infection is associated with significant alteration of gut microbiota, which differ depending on the stage of CHB disease progression. Different mechanisms of the hepatic injury from gut microbiota dysbiosis have also been proposed based on findings of increased intestinal permeability to toxins, disruption of normal bacterial metabolism, and colonization of the gut by oral microbiota. New treatment methods targeting gut microbiota in CHB, such as probiotics and faecal microbiota transplant, have also gained promising results in recent years. The current review recapitulated the most recent investigations into the relationship between gut microbiota and CHB to provide research directions towards the new therapeutic target of CHB.

show abstract

Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model

Cited by 21 publications

References 18 publications

Serum metabolite profiling yields insights into health promoting effect of A. muciniphila in human volunteers with a metabolic syndrome

Serum metabolite profiling yields insights into health promoting effect of A. muciniphila in human volunteers with a metabolic syndrome

Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study

The role of gut microbiota in hepatitis B disease progression and treatment

Contact Info

Product

Resources

About